LABU Performance — Direxion Daily S&P Biotech Bull 3X Shares
Data updated: 2026-09-28
LABU returned +42.80% year to date and +274.67% over one year to Jul 2026. Annualised returns are +24.07% over 3 years and −26.72% over 5 years. The fund beat its Trading - Leveraged category average: $100 invested three years ago grew to $191, against $136 for the category, and to $375 over one year, against $105. Volatility over the past three years was 79.97% a year. In the 12 months to Jul 2026 the fund lost a net $1.1B, and assets reached $494.36M.
LABU Growth of $100
What $100 invested in Direxion Daily S&P Biotech Bull 3X Shares grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Trading - Leveraged category average over the same months.
| Period | LABU | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $375 | $105 |
| 3 years (Aug 2023 – Jul 2026) | $191 | $136 |
| 5 years (Aug 2021 – Jul 2026) | $21 | $130 |
| Since data start (Aug 2019 – Jul 2026) | $25 | $147 |
LABU Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +42.80% |
| 1 year | +274.67% |
| 3 years (annualised) | +24.07% |
| 5 years (annualised) | −26.72% |
LABU Annual Returns
Calendar-year total returns of Direxion Daily S&P Biotech Bull 3X Shares, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +42.80% |
| 2025 | +78.07% |
| 2024 | −25.92% |
| 2023 | −13.43% |
| 2022 | −80.29% |
| 2021 | −64.30% |
| 2020 | +74.72% |
| 2019 (Aug–Dec) | +25.21% |
LABU Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +4.2% | +4.1% | −3.7% | +6.7% | +10.1% | +49.3% | −22.0% | — | — | — | — | — |
| 2025 | +6.3% | −14.0% | −25.9% | −0.3% | −16.9% | +12.5% | +7.5% | +13.4% | +35.6% | +40.0% | +27.1% | −4.1% |
| 2024 | −8.7% | +36.0% | −12.1% | −31.9% | +13.5% | +10.7% | +19.0% | +4.3% | −8.7% | −7.2% | +4.8% | −28.1% |
| 2023 | +18.7% | −21.7% | −25.0% | +13.4% | +11.6% | −5.0% | +1.9% | −18.4% | −22.7% | −28.4% | +41.5% | +58.7% |
| 2022 | −45.2% | −15.5% | −5.9% | −48.0% | −28.6% | +16.2% | +24.2% | +3.8% | −19.4% | +6.0% | +1.8% | −6.4% |
| 2021 | +25.4% | −12.6% | −28.6% | 0.0% | −20.2% | +17.4% | −26.0% | +21.8% | −17.0% | −3.5% | −20.5% | −15.3% |
| 2020 | −19.5% | −1.9% | −50.1% | +62.9% | +31.6% | +22.0% | −9.9% | +4.8% | −4.4% | 0.0% | +61.5% | +16.2% |
| 2019 | — | — | — | — | — | — | — | −19.8% | −16.1% | +20.4% | +48.3% | +4.3% |
LABU Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 79.97%
- 3-year Sharpe ratio: 0.24 (vs 4.5% risk-free rate)
- Best month: +58.70% (Dec 2023)
- Worst month: −31.87% (Apr 2024)
LABU Fund Flows
Monthly money in and out of Direxion Daily S&P Biotech Bull 3X Shares, from SEC Form N-PORT.
- 12-month net flow: −$1.1B
- 12-month gross sales (incl. reinvestments): $671.6M
- Sales ÷ redemptions: 0.37×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $54.3M | $94.8M | −$40.4M |
| Jun 2026 | $121.5M | $276.1M | −$154.6M |
| May 2026 | $95.1M | $98.5M | −$3.4M |
| Apr 2026 | $118.3M | $196.4M | −$78.1M |
| Mar 2026 | $180.2M | $168.1M | $12.1M |
| Feb 2026 | $7.9M | $51.8M | −$43.9M |
| Jan 2026 | $8.7M | $208.9M | −$200.2M |
| Dec 2025 | $7.6M | $116.4M | −$108.7M |
| Nov 2025 | $17.7M | $144.6M | −$126.9M |
| Oct 2025 | $5.7M | $206.6M | −$200.9M |
| Sep 2025 | $20.3M | $121.8M | −$101.5M |
| Aug 2025 | $34.3M | $110.6M | −$76.3M |
LABU Assets Under Management
Net assets of Direxion Daily S&P Biotech Bull 3X Shares by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $494.36M |
| 2026-04-30 | $518.89M |
| 2026-01-31 | $576.37M |
| 2025-10-31 | $817.11M |
| 2025-07-31 | $630.59M |
| 2025-04-30 | $602.99M |
| 2025-01-31 | $836.12M |
| 2024-10-31 | $893.42M |
| 2024-07-31 | $1.09B |
| 2024-04-30 | $949.09M |
| 2024-01-31 | $1.03B |
| 2023-10-31 | $678.22M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.